Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Irofulven · LP-100, MGI-114

Small molecule · Cytotoxic · developed by Eisai

Phase 2 Most advanced trial (none active)

1 Registered trials

What is Irofulven?

Irofulven is a semisynthetic sesquiterpene derivative that alkylates DNA and protein macromolecules, forming adducts and arresting cells in S-phase. It requires NADPH-dependent metabolism for activity and shows greater in vitro activity against epithelial tumor cells. It is studied in metastatic castration-resistant prostate cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: LP-100, MGI-114
Drug type: Small molecule
Mechanism: Cytotoxic
Pathways: DNA alkylation, S-phase cell cycle arrest
Therapy area: Oncology
Developer: Eisai Inc.
In trials of: ALLR
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: 6B799IH05A

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT03643107	Phase 2	Metastatic Castration-Resistant Prostate Cancer Patients	Completed	ALLR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Metastatic Castration-Resistant Prostate Cancer Patients

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z